PNPLA2

Chr 11AR

patatin like domain 2, triacylglycerol lipase

Also known as: 1110001C14Rik, ATGL, FP17548, PEDF-R, TTS-2.2, TTS2, iPLA2zeta

The protein catalyzes the initial step in triglyceride hydrolysis in lipid droplets and plays a key role in energy homeostasis by breaking down stored fats. Mutations cause neutral lipid storage disease with myopathy, an autosomal recessive disorder characterized by abnormal lipid accumulation affecting muscle tissue. The gene is not highly constrained against loss-of-function variants.

OMIMResearchSummary from RefSeq, OMIM, UniProt
LOFmechanismARLOEUF 0.741 OMIM phenotype
Clinical SummaryPNPLA2
🧬
Gene-Disease Validity (ClinGen)
neutral lipid storage myopathy · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
53 unique Pathogenic / Likely Pathogenic· 225 VUS of 539 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.74LOEUF
pLI 0.004
Z-score 2.36
OE 0.39 (0.220.74)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
-0.01Z-score
OE missense 1.00 (0.911.10)
308 obs / 307.6 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios
LoF OE0.39 (0.220.74)
00.351.4
Missense OE1.00 (0.911.10)
00.61.4
Synonymous OE1.06
01.21.6
LoF obs/exp: 7 / 17.8Missense obs/exp: 308 / 307.6Syn Z: -0.55
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
strongPNPLA2-related neutral lipid storage disease with myopathyLOFAR

Predictions shown for reference only — model trained on dominant genes, not applicable to AR conditions.

DN
0.6550th %ile
GOF
0.81top 10%
LOF
0.3163th %ile

The Badonyi & Marsh prediction model was trained exclusively on dominant disease genes. Predictions are not reliable for genes with autosomal recessive inheritance and are shown at reduced opacity for reference only.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

539 submitted variants in ClinVar

Classification Summary

Pathogenic44
Likely Pathogenic9
VUS225
Likely Benign224
Benign13
Conflicting9
44
Pathogenic
9
Likely Pathogenic
225
VUS
224
Likely Benign
13
Benign
9
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
23
3
18
0
44
Likely Pathogenic
8
1
0
0
9
VUS
7
198
19
1
225
Likely Benign
0
4
92
128
224
Benign
0
2
7
4
13
Conflicting
9
Total38208136133524

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

PNPLA2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →